Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation

Area of Science:

• Hematology
• Immunology
• Molecular Biology

Background:

• ZAP-70 (zeta-chain-associated protein kinase 70 kDa) expression is a key biomarker in Chronic Lymphocytic Leukemia (CLL).
• Comparing anti-ZAP-70 antibody clones and analytical methods is crucial for accurate clinical correlation.
• Previous studies highlighted the need for validation of ZAP-70 expression analysis in CLL.

Purpose of the Study:

• To compare ZAP-70 expression analysis methods in untreated CLL patients.
• To evaluate the correlation between ZAP-70 expression and established CLL prognostic markers.
• To determine the optimal methodology for ZAP-70 assessment in CLL.

Main Methods:

• Multicolor flow cytometry was used to analyze ZAP-70, CD38, CD69, CD26, CD49d, and CD27 in 45 untreated CLL patients.
• Four distinct ZAP-70 expression analysis methods and a scoring system were developed and tested.
• Correlation analyses were performed between ZAP-70 scores, IGHV mutational status, and cytogenetic abnormalities (del 13q14, trisomy 12).

Main Results:

• A strong correlation was observed between ZAP-70 expression levels and immunoglobulin heavy chain variable (IGHV) mutational status.
• The developed scoring system, particularly when using multiple analysis methods, significantly improved the reliability of ZAP-70 assessment (P < 0.001).
• Correlations were also found between ZAP-70 scores and del 13q14 (P=0.017) and trisomy 12 (P=0.011), as well as CD38 and CD49d expression.

Conclusions:

• ZAP-70 expression is a superior predictor of IGHV mutational status in CLL compared to other tested biomarkers.
• Employing multiple analytical methods for ZAP-70 assessment provides more robust and reliable results than single-method approaches.
• Standardization of routine analysis for CD38, CD49d, and CD26 is necessary for consistent clinical application in CLL management.